A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BLISIBIMOD ADMINISTRATION IN SUBJECTS WITH IGA NEPHROPATHY

Registry ID

AN-IGN3321

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

ANTHERA PHARMACEUTICALS INC

Last update

2014-11-21

Conditions

• NEPHROPATHY

Related clinical trials

• A PROSPECTIVE, COMPARATIVE, RANDOMIZED, MULTI-CENTER, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PHASE 2A STUDY OF THE SAFETY AND EFFICACY OF CMX-2043 FOR PERIPROCEDURAL INJURY PROTECTION IN SUBJECTS UNDERGOING CORONARY ANGIOGRAPHY AT RISK OF RADIO-CONTRAST INDUCED NEPHROPATHY (CARIN)

View on source registry